SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.48 ^USD	+1.37%		+8.03%	+39.62%

May. 19	Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI
May. 01	SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	CI

SELLAS Life Sciences Group, Inc Appoints Gregory M. Torre as Chief Regulatory Officer and Senior Vice President, Technical Operations Effective April 27, 2018

April 24, 2018 at 05:01 pm EDT

On April 19, 2018, SELLAS Life Sciences Group, Inc. and Gregory M. Torre, Ph.D., J.D. mutually agreed that his employment as Chief Regulatory Officer and Senior Vice President, Technical Operations of the company would cease, effective April 27, 2018. The company and Dr. Torre entered into a severance agreement in accordance with the terms of Dr. Torre’s employment agreement.

Latest news about SELLAS Life Sciences Group, Inc.

Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	May. 18	CI
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	May. 01	CI
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	Apr. 29	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call	Mar. 26
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	Mar. 26	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Top Midday Decliners	Mar. 15	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	Mar. 15	MT
SELLAS Life Sciences Group, Inc. announced a financing transaction	Mar. 14	CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes	Mar. 08	CI
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients	Jan. 09	CI
Top Midday Decliners	Jan. 04	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Thursday as Traders Mull Fed Meeting Minutes	Jan. 04	MT
SELLAS Life Sciences Plans Public Offering of Stock, Warrants; Shares Drop Premarket	Jan. 04	MT
SELLAS Life Sciences Group, Inc. announced that it expects to receive $8.999813 million in funding	Jan. 03	CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call	Jan. 03
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma	Dec. 27	CI
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	Dec. 27	MT
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia	Dec. 14	CI
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia	Dec. 04	CI
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia	Nov. 29	CI
Sellas Life Sciences Gets Favorable Meeting Feedback From FDA	Nov. 13	DJ

Chart SELLAS Life Sciences Group, Inc.

Duration

Period

More charts

Company Profile

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.48 USD

Average target price

5.833 USD

Spread / Average Target

+294.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SELLAS LIFE SCIENCES GROUP, INC.	+39.62%	85.48M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
BIONTECH SE	-12.38%	22.31B
ARGENX SE	-3.38%	21.6B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B
LEGEND BIOTECH CORPORATION	-24.50%	8.28B

Bio Therapeutic Drugs